Blueprint Medicines, a Cambridge early-stage cancer therapeutics firm, has scored a $40 million Series A funding round from Boston’s Third Rock Ventures, the largest A round financing the venture capital firm has ever made.

The startup plans to use the funds and its own compound library and Insights-to-Validation platform to develop personalized treatments based on targeted molecular aberrations of cancer.

SOURCE